1,506 results on '"Eto, Masatoshi"'
Search Results
2. Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement
3. Optimization of Extended Pelvic Lymph Node Dissection Side for Prostate Cancer
4. Papillary renal neoplasm with reverse polarity has low frequency of alterations in chromosomes 7, 17, and Y
5. Clinical practice guidelines for telesurgery 2022: Committee for the promotion of remote surgery implementation, Japan Surgical Society
6. Current status and future perspective of immunotherapy for renal cell carcinoma
7. Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy
8. Prediction of undetectable circulating tumor DNA by comprehensive genomic profiling assay in metastatic prostate cancer: the SCRUM-Japan MONSTAR SCREEN project
9. Predictive model of castration resistance in advanced prostate cancer by machine learning using genetic and clinical data: KYUCOG-1401-A study
10. Functional outcomes in robot-assisted partial nephrectomy with three-dimensional images reconstructed from computed tomography: a propensity score-matched comparative analysis
11. Genomic profiling and clinical utility of circulating tumor DNA in metastatic prostate cancer: SCRUM-Japan MONSTAR SCREEN project
12. Field experiment of a telesurgery system using a surgical robot with haptic feedback
13. ASO Author Reflections: Treatment Choice for Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy
14. Improved urinary continence recovery after robot-assisted radical prostatectomy with lateral pelvic fascia preservation
15. Oxidative stress in peroxisomes induced by androgen receptor inhibition through peroxisome proliferator–activated receptor promotes enzalutamide resistance in prostate cancer
16. Telesurgery and telesurgical support using a double-surgeon cockpit system allowing manipulation from two locations
17. Virtual reality environments to train soft skills in medical and nursing education: a technical feasibility study between France and Japan
18. Steroids-producing nodules: a two-layered adrenocortical nodular structure as a precursor lesion of cortisol-producing adenoma
19. Reliability, validity, and responsiveness of the Japanese version of the EORTC QLQ-ELD14 in evaluating the health-related quality of life of elderly patients with cancer
20. Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trial
21. Interstitial pneumonia after regression by olaparib for neuroendocrine prostate cancer with BRCA1 mutation: a case report
22. Prognostic value of PD-L1 expression in recurrent renal cell carcinoma after nephrectomy: a secondary analysis of the ARCHERY study
23. Comparison of therapeutic features and oncologic outcome in patients with pN1 prostate cancer among robot-assisted, laparoscopic, or open radical prostatectomy
24. Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study
25. Novel nomogram to predict biochemical recurrence-free survival after radical prostatectomy
26. Impact of trough abiraterone level on adverse events in patients with prostate cancer treated with abiraterone acetate
27. 2.5-mm articulated endoluminal forceps using a compliant mechanism
28. Prognostic significance of pathogenic variants in BRCA1, BRCA2, ATM and PALB2 genes in men undergoing hormonal therapy for advanced prostate cancer
29. Radical nephroureterectomy for UTUC conferred survival benefits irrespective of age and comorbidities
30. Evaluation of bone density and skeletal muscle mass after sleeve gastrectomy using computed tomography method
31. Prognostic impact of CD73/adenosine 2A receptor (A2AR) in renal cell carcinoma and immune microenvironmental status with sarcomatoid changes and rhabdoid features
32. TFE3-immunopositive papillary renal cell carcinoma: A clinicopathological, immunohistochemical, and genetic study
33. Validation of user-friendly models predicting extracapsular extension in prostate cancer patients
34. Biomarker analyses in patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
35. Initial experience with vibegron for the treatment of neurogenic lower urinary tract storage dysfunction in patients with spinal cord injury
36. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
37. Adverse Events of Abiraterone Acetate vs Enzalutamide
38. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
39. Effect of HLA genotype on intravesical recurrence after bacillus Calmette–Guérin therapy for non-muscle-invasive bladder cancer
40. Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis
41. T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma
42. Cancer genomic profiling identified dihydropyrimidine dehydrogenase deficiency in bladder cancer promotes sensitivity to gemcitabine
43. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation
44. HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability
45. Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer
46. Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
47. Impact of proton pump inhibitors on the efficacy of androgen receptor signaling inhibitors in metastatic castration‐resistant prostate cancer patients.
48. Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
49. Adverse Events of Cabozantinib Plus Nivolumab Versus Ipilimumab Plus Nivolumab
50. Independent validation of genetic risk model to progression after intravesical bacillus Calmette‐Guérin therapy for non‐muscle invasive bladder cancer
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.